IP Library › Granted Patent US 10,352,859
Granted Patent B2
US 10,352,859 · App. 15/024,216 · Granted Jul 16, 2019

Method for determining quantity of biological material in tissue section

Inventors: Fuminori Okada (Tokyo, JP); Takuji Aimiya (Nishitokyo, JP); Kohsuke Gonda (Sendai, JP); Noriaki Ohuchi (Sendai, JP); Mika Watanabe (Sendai, JP)
Assignee: KONICA MINOLTA, INC.
G01N21/6458G01N21/6428G01N33/5088G01N33/56966G01N2021/6439G01N2201/12G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,352,859
App. No.
15/024,216
Granted
Jul 16, 2019
Kind
B2
Abstract

An object of the present invention is to provide a method of detecting a specific tissue or cell in a sample tissue section and accurately specifying both the position(s) and amount of a biological substance of interest that is expressed on the specific tissue or cell. The method of quantifying a biological substance in a tissue section according to the present invention comprises: (1) performing bright-field observable immunostaining that specifically stains a first biological substance in the tissue section (first immunostaining); (2) performing immunostaining with a fluorescent substance-containing nanoparticle that specifically stains a second biological substance in the tissue section (second immunostaining); (3) specifying the expression position(s) of the second biological substance in the tissue section by comparing the position of a stained image of the first immunostaining and the position of a stained image of the second immunostaining; and (4) determining the expression amount of the second biological substance by measuring the fluorescence intensity of the stained image of the second immunostaining.

Claims (20)

1. A method of quantifying a biological substance in a tissue section, said method comprising:

(1) performing bright-field observable enzyme immunostaining that specifically stains a first biological substance in said tissue section (first immunostaining);

(2) performing immunostaining with a fluorescent-containing nanoparticle that specifically stains a second biological substance in said tissue section (second immunostaining);

(3) specifying the expression position(s) of said second biological substance in said tissue section by comparing the position of a stained image of said first immunostaining and position of a stained image of said second immunostaining; and

(4) determining the expression amount of said second biological substance by measuring the fluorescence intensity of said stained image of said second immunostaining.

2. The method according to claim 1 , wherein said fluorescence intensity of said stained image of said second immunostaining is measured at a position(s) where said stained image of said first immunostaining and that of said second immunostaining overlap with each other.

3. The method according to claim 1 , wherein said first immunostaining and said second immunostaining are performed on the same tissue section.

4. The method according to claim 1 , wherein the first biological substance comprises at least one of CD31, CD34, or podoplanin.

5. The method according to claim 1 , wherein at least one of following condition (1) or (2) is satisfied:

(1) the first biological substance comprises at least one of CD31, CD34, or podoplanin; and

(2) the second biological substance comprises at least one of VEGFR-1, VEGFR-2, or VEGFR-3.

6. The method according to claim 1 , wherein the fluorescent substance-containing nanoparticle comprises at least one of polystyrene, polyamide, polylactic acid, polyacrylonitrile, polyglycidyl methacrylate, polymelamine, polyuria, polybenzoguanamine, polyfuran, polyxylene, phenol resins, polysaccharides, or silica.

7. The method according to claim 1 , wherein the second immunostaining is performed with fluorescent substance-containing nanoparticles, and an average particle size of the fluorescent substance-containing nanoparticles is 10 to 500 nm.

8. The method according to claim 7 , wherein at least one of following condition (1) or (2) is satisfied:

(1) the first biological substance comprises at least one of CD31, CD34, or podoplanin; and

(2) the second biological substance comprises at least one of VEGFR-1, VEGFR-2, or VEGFR-3.

9. The method according to claim 7 , wherein the average particle size of the fluorescent substance-containing nanoparticles is not more than 200 nm.

10. The method according to claim 7 , wherein a variation coefficient in the particle size of the fluorescent substance-containing nanoparticles is 20% or less.

11. The method according to claim 10 , wherein the variation coefficient is 5 to 15%.

12. The method according to claim 1 , wherein the fluorescence intensity is determined based on a number of bright spots, the fluorescence brightness, or the both.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2016
From: OKADA, FUMINORI; AIMIYA, TAKUJI; GONDA, KOHSUKE; OHUCHI, NORIAKI; WATANABE, MIKA
To: KONICA MINOLTA, INC.
Reel/Frame 038083/0749 →
Priority Claims (1)
JP 2013-199782 · Sep 26, 2013 · national
Continuity (1)
Related Publication 20160216209A1 · Jul 28, 2016